Current Challenges in Metastatic Breast Cancer:

Article

This series of case presentations (five individual cases) will provide oncologists and other healthcare professionals with strategies for evaluating evidence-based data on the latest treatments in metastatic breast cancer (MBC) and the application of that data into the development of individualized approaches to care, including overcoming resistance, in order to optimize management and outcomes for patients.

Current Challenges in Metastatic Breast Cancer:

Patient Management and Treatment Strategies

Interactive Case Challenge Series

This series of case presentations (five individual cases) will provide oncologists and other healthcare professionals with strategies for evaluating evidence-based data on the latest treatments in metastatic breast cancer (MBC) and the application of that data into the development of individualized approaches to care, including overcoming resistance, in order to optimize management and outcomes for patients.

Go to Activity

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Related Content
Linvoseltamab monotherapy achieved minimal residual disease negativity in 95% of patients with newly diagnosed multiple myeloma.

Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma

Sabrina Serani
December 8th 2025
Article

Linvoseltamab monotherapy achieved minimal residual disease negativity in 95% of patients with newly diagnosed multiple myeloma.

Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

Talquetamab plus teclistamab led to an ORR and CR or better rate of 79% and 53%, respectively, in multiple myeloma with true extramedullary disease.

Talquetamab Combo Yields Responses in Multiple Myeloma With True EMD

Tim Cortese
December 8th 2025
Article

Talquetamab plus teclistamab led to an ORR and CR or better rate of 79% and 53%, respectively, in multiple myeloma with true extramedullary disease.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

3 Things You Should Know About ADCs in Early-Stage TNBC and Considerations for Implementation

3 Things You Should Know About ADCs in Early-Stage TNBC and Considerations for Implementation

ONCOLOGY Staff
December 8th 2025
Article

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer and their unique safety profiles.

5-Year+ BRUIN Follow-Up Shows Continued Response With Pirtobrutinib in CLL/SLL

5-Year+ BRUIN Follow-Up Shows Continued Response With Pirtobrutinib in CLL/SLL

Caroline Seymour
December 8th 2025
Article

“Pirtobrutinib continues to show favorable efficacy and promising overall survival [OS],” said William G. Wierda, MD, PhD.